de Luis Daniel, Primo David, Izaola Olatz, López Gómez Juan José
Center of Investigation of Endocrinology and Clinical Nutrition, Medicine School, Department Endocrinology and Nutrition, Hospital Clinico Universitario, University of Valladolid, Valladolid, Spain.
Ann Nutr Metab. 2025 May 26:1-8. doi: 10.1159/000546418.
Sarcopenia is a condition characterized by muscle mass loss. Some investigations have demonstrated the role of brain-derived neurotrophic factor (BDNF) as a protector against the presence of sarcopenia in patients with chronic kidney disease. We aimed to explore the role of circulating BDNF in the development of sarcopenia among individuals with disease-related malnutrition (DRM).
A total of 160 patients diagnosed with DRM according to the Global Leadership Initiative on Malnutrition (GLIM) criteria were enrolled. Anthropometric data, muscle mass assessed via ultrasound at the rectus femoris quadriceps (RFQ) level, bioelectrical impedance analysis (skeletal muscle mass [SMM], appendicular skeletal muscle mass [aSMM], and appendicular skeletal muscle mass index [aSMMI]), handgrip strength, biochemical parameters, dietary intake, and circulating levels of BDNF were measured.
A total of 55 patients (34.4%) were classified as sarcopenic, while 105 patients (65.6%) were classified as non-sarcopenic. Phase angle (-0.6 ± 0.2°; p = 0.01), reactance (-5.8 ± 2.1 Ohms; p = 0.03), SMM (-3.3 ± 0.2 kg; p = 0.04), aSMM (-2.1 ± 0.3 kg; p = 0.03), aSMMI (-0.8 ± 0.2 kg; p = 0.03), dominant muscle area (-0.7 ± 0.2 cm2; p = 0.04), and dominant Y-axis thickness (-0.4 ± 0.1 cm; p = 0.03) were worse in patients with sarcopenia. Muscle strength was higher in non-sarcopenic patients (8.5 ± 1.2 kg; p = 0.01). Circulating BDNF levels were significantly higher in non-sarcopenic patients compared to sarcopenic patients (94.7 ± 3.9 ng/mL; p = 0.01). Logistic regression analysis indicated a reduced risk of sarcopenia (OR = 0.16, 95% CI = 0.11-0.43; p = 0.03) in patients with higher BDNF levels, after adjusting for body mass index, gender, energy intake, and age.
Our study identified an association between low serum BDNF levels and sarcopenia in patients with DRM.
肌肉减少症是一种以肌肉质量丧失为特征的病症。一些研究表明，脑源性神经营养因子（BDNF）在慢性肾脏病患者中具有预防肌肉减少症的作用。我们旨在探讨循环BDNF在疾病相关性营养不良（DRM）个体肌肉减少症发生发展中的作用。
根据全球营养不良领导倡议（GLIM）标准，共纳入160例诊断为DRM的患者。测量人体测量数据、通过超声在股直肌四头肌（RFQ）水平评估的肌肉质量、生物电阻抗分析（骨骼肌质量[SMM]、四肢骨骼肌质量[aSMM]和四肢骨骼肌质量指数[aSMMI]）、握力、生化参数、饮食摄入量以及BDNF的循环水平。
共有55例患者（34.4%）被分类为肌肉减少症患者，105例患者（65.6%）被分类为非肌肉减少症患者。肌肉减少症患者的相位角（-0.6±0.2°；p = 0.01）、电抗（-5.8±2.1欧姆；p = 0.03）、SMM（-3.3±0.2千克；p = 0.04）、aSMM（-2.1±0.3千克；p = 0.03）、aSMMI（-0.8±0.2千克；p = 0.03）、优势肌肉面积（-0.7±0.2平方厘米；p = 0.04）和优势Y轴厚度（-0.4±0.1厘米；p = 0.03）较差。非肌肉减少症患者的肌肉力量较高（8.5±1.2千克；p = 0.01）。与肌肉减少症患者相比，非肌肉减少症患者的循环BDNF水平显著更高（94.7±3.9纳克/毫升；p = 0.01）。在调整体重指数、性别、能量摄入量和年龄后，逻辑回归分析表明，BDNF水平较高的患者发生肌肉减少症的风险降低（OR = 0.16，95%CI = 0.11 - 0.43；p = 0.03）。
我们的研究发现DRM患者血清BDNF水平低与肌肉减少症之间存在关联。
